Atlas Trials

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Clinical trial NCT03671330 · COMPLETED

Trial details

NCT number
NCT03671330
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2018-08-29
Primary completion
2022-04-25
Enrollment
327

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.